SNNA News and Press, Sienna Biopharmaceuticals Inc. From 08/13/19

Covetrus (NASDAQ: CVET )  -36%  on Q2 earnings . More news on: Covetrus, Inc., Bloom Energy Corporation, BEST Inc., Stocks on the move, Read more ...

Thinly traded nano cap Sienna Biopharmaceuticals (NASDAQ: SNNA ) has hired  Cowen and Company to advise it on financial and strategic alternatives aimed at boosting shareholder value. More news on: Sienna Biopharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read ...

WESTLAKE VILLAGE, Calif., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the Company has retained Cowen as an independent financial advisor to assist in exploring financial and strategic alter...

The Technology Platform Sienna ( SNNA ) is a small-cap ($23.97M) pharmaceutical that was publicly listed in 2017. Its scientific forte is the clinical development of tissue–targeted kinase inhibitors (TTKI.) to treat diverse chronic inflammatory and immunologic ailments. The techno...

The following slide deck was published by Sienna Biopharmaceuticals, Inc. in conjunction with this Read more ...

Our weekend preview of upcoming IPOs, earnings reports, conference presentations, investor days, IPO lockup expirations, FDA decisions, Barron's mentions and other key events that could impact stocks. If you are interested in listening to Stocks To Watch to start your Sunday (you ca...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , iTunes...

WESTLAKE VILLAGE, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna, is scheduled to presen...

Gainers:  Provention Bio (NASDAQ: PRVB ) +296% . Vuzix Corporation (NASDAQ: VUZI ) +54% . Xynomic Pharmaceuticals Holdings (NASDAQ: XYN ) +46% . Tableau Software (NYSE: DATA ) +35% . Hi-Crush (NYSE: HCR ) +31% . Beyond Meat (NASDAQ: BYND ) +24% . Workhorse Group (NASDAQ: WKHS ) ...

-- Phase 2b Trial Results Demonstrated SNA-120 Had Significant Impact on Psoriasis and Was Well-Tolerated WESTLAKE VILLAGE, Calif., June 10, 2019 (GLOBE NEWSWIRE) -- Sienna Biopharmaceuticals, Inc. (Nasdaq:SNNA), a clinical-stage biopharmaceutical company, today announced that the r...